Targeting osseous metastases: Rationale and development of radio-immunotherapy for prostate cancer Journal Article

  


Authors: Morris, M. J.; Pandit-Taskar, N.; Divgi, C.; Larson, S.; Scher, H. I.
Article Title: Targeting osseous metastases: Rationale and development of radio-immunotherapy for prostate cancer
Abstract: For patients with metastatic prostate cancer, bone is the primary site of tumor localization and the major cause of disease-related morbidity and mortality. Hormonal therapy and chemotherapy alone cannot eradicate disease harbored in bone. The delivery of radiotherapy to the reservoir of disease is an approach previously only achievable using bone-seeking radiopharmaceuticals. Now, however, with the identification of tumor-specific targets, antibodies are being used to deliver radiotherapy to these sites. In this article, we review the rationale behind this approach, the targets being explored, the radiation sources available, and the antibodies currently under clinical development. Copyright © 2004 by Current Science Inc.
Keywords: cancer chemotherapy; bone neoplasms; unclassified drug; clinical trial; review; cancer localization; doxorubicin; interferon; bone metastasis; drug targeting; cancer patient; ibritumomab tiuxetan; rituximab; radiopharmaceuticals; unindexed drug; quality of life; bone marrow suppression; morbidity; cancer pain; cancer mortality; vinblastine; monoclonal antibody; cancer hormone therapy; prostate cancer; prostatic neoplasms; drug cost; antibodies, monoclonal; iodine 131; drug distribution; radiopharmaceutical agent; drug tissue level; ketoconazole; immunologic factors; radioimmunotherapy; indium 111; tositumomab i 131; antibodies, neoplasm; bone marrow toxicity; yttrium 90; monoclonal antibody b.72.3; lexidronam samarium sm 153; samarium 153; strontium 89; estramustine; cd20 antibody; etidronic acid; phosphorus 32; rhenium 186; etidronic acid re 186; phosphate p 32; copper 67; humans; human; male; monoclonal antibody cc49; chloride sr 89; monoclonal antibody cc49 i 131; monoclonal antibody pay 276; monoclonal antibody pay 276 in 111
Journal Title: Current Oncology Reports
Volume: 6
Issue: 3
ISSN: 1523-3790
Publisher: Springer  
Date Published: 2004-06-01
Start Page: 222
End Page: 229
Language: English
PROVIDER: scopus
PUBMED: 15066234
DOI: 10.1007/s11912-004-0053-y
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-5444262113&partnerID=40&md5=d1dd027a1ad6623e253be9e611f83790
Notes: Curr. Oncol. Rep. -- Export Date: 16 June 2014 -- CODEN: CORUA C2 - 15066234 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Chaitanya Divgi
    163 Divgi
  2. Michael Morris
    579 Morris
  3. Neeta Pandit-Taskar
    343 Pandit-Taskar
  4. Steven M Larson
    959 Larson
  5. Howard Scher
    1130 Scher
Related MSK Work